While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.
Kevin Venner
Advertisement
Group Leader, Biostatisticians, Almac Clinical Technologies
Articles by Kevin Venner
It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
3
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
4
Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs
5